A brief overview of preeclampsia

Noura Al-Jameil, Farah Aziz Khan, Mohammad Fareed Khan, Hajera Tabassum, Noura Al-Jameil, Farah Aziz Khan, Mohammad Fareed Khan, Hajera Tabassum

Abstract

Preeclampsia (PE) is a leading cause of maternal mortality and morbidity worldwide. It occurs in women with first or multiple pregnancies and is characterized by new onset hypertension and proteinuria. Improper placentation is mainly responsible for the disease. If PE remains untreated, it moves towards more serious condition known as eclampsia. Hypertension, diabetes mellitus, proteinuria, obesity, family history, nulliparity, multiple pregnancies and thrombotic vascular disease contribute as the risk factors for PE. PE triggered metabolic stress causes vascular injury, thus contributing to the development of cardiovascular disease (CVD) and/or chronic kidney disease (CKD) in future. This risk appears to be increased especially in women with a history of recurrent PE and eclampsia. Clinically increased serum levels of sFlt-1 and decreased placental growth factor (PIGF) and vascular endothelial growth factor (VEGF) represent the severe condition of PE. The clinical findings of sever PE are assorted by the presence of systemic endothelial dysfunction, microangiopathy, the liver (hemolysis, elevated liver function tests and low platelet count, namely HELLP syndrome) and the kidney (proteinuria). The early detection of PE is one of the most important goals in obstetrics.

Keywords: Eclampsia; Hypertension; Microangiopathy; Preeclampsia; Proteinuria.

References

    1. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18(8):2281–2284.
    1. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol. 1990;163(2):460–465.
    1. Sibai BM, Gordon T, Thom E, Caritis SN, Klebanoff M, McNellis D, Paul RH. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 1995;172(2 Pt 1):642–648.
    1. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22(2):203–212.
    1. Walker JJ. Pre-eclampsia. Lancet. 2000;356(9237):1260–1265.
    1. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357(9249):53–56.
    1. Page EW. The relation between hydatid moles, relative ischemia of the gravid uterus and the placental origin of eclampsia. Am J Obstet Gynecol. 1939;37:291–293.
    1. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161(5):1200–1204.
    1. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol. 2000;24(1):24–28.
    1. Lafayette RA, Druzin M, Sibley R, Derby G, Malik T, Huie P, Polhemus C. et al. Nature of glomerular dysfunction in pre-eclampsia. Kidney Int. 1998;54(4):1240–1249.
    1. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.
    1. Ananth S, Maynard SE, AnaStillmann IE. Preeclampsia: A renal prespective. Kid Inter. 2005;67:2101–2113.
    1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.
    1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785–799.
    1. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardottir S, Stefansson H. et al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet. 2001;9(10):758–764.
    1. Keyes LE, Armaza JF, Niermeyer S, Vargas E, Young DA, Moore LG. Intrauterine growth restriction, preeclampsia, and intrauterine mortality at high altitude in Bolivia. Pediatr Res. 2003;54(1):20–25.
    1. Chesley LC. History and epidemiology of preeclampsia-eclampsia. Clin Obstet Gynecol. 1984;27(4):801–820.
    1. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Mol Aspects Med. 2007;28(2):192–209.
    1. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006;13(5):680–686.
    1. Catov JM, Ness RB, Kip KE, Olsen J. Risk of early or severe pre-eclampsia related to pre-existing conditions. Int J Epidemiol. 2007;36(2):412–419.
    1. Fischer MJ, Lehnerz SD, Hebert JR, Parikh CR. Kidney disease is an independent risk factor for adverse fetal and maternal outcomes in pregnancy. Am J Kidney Dis. 2004;43(3):415–423.
    1. Fink JC, Schwartz SM, Benedetti TJ, Stehman-Breen CO. Increased risk of adverse maternal and infant outcomes among women with renal disease. Paediatr Perinat Epidemiol. 1998;12(3):277–287.
    1. McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis. 2010;55(6):1026–1039.
    1. Lim KH, Friedman SA, Ecker JL, Kao L, Kilpatrick SJ. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 1998;178(5):1067–1071.
    1. Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, Kim MR, Espinoza J. et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med. 2005;18(1):9–16.
    1. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17(1):3–18.
    1. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP. et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9–23.
    1. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008;93(1):260–266.
    1. Woolcock J, Hennessy A, Xu B, Thornton C, Tooher J, Makris A, Ogle R. Soluble Flt-1 as a diagnostic marker of pre-eclampsia. Aust N Z J Obstet Gynaecol. 2008;48(1):64–70.
    1. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246(4935):1309–1312.
    1. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271(30):17629–17634.
    1. Chappell JC, Taylor SM, Ferrara N, Bautch VL. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell. 2009;17(3):377–386.
    1. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380(6573):439–442.
    1. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168(2):639–648.
    1. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998;140(4):947–959.
    1. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265(2 Pt 2):H586–592.
    1. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8(8):831–840.
    1. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J. et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9(7):936–943.
    1. Cackovic M, Buhimschi CS, Zhao G, Funai EF, Norwitz ER, Kuczynski E, Lockwood CJ. et al. Fractional excretion of tumor necrosis factor-alpha in women with severe preeclampsia. Obstet Gynecol. 2008;112(1):93–100.
    1. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension. 2008;52(2):402–407.
    1. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension. 2005;45(2):258–263.
    1. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R. et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998;59(6):1540–1548.
    1. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
    1. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649.
    1. Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS. et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med. 2008;205(2):491–501.
    1. Wallenburg HCS. In: Handbook of Hypertension. Rubin PC, editor. New York: Elsevier Science; 1988. Hemodynamics of hypertensive pregnancy; pp. 66–101.
    1. Victor R, Mark A. In: Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. Laragh J, Brenner B, editors. New York, NY: Raven Press; 1995. The sympathetic nervous system in human hypertension; pp. 865–887.
    1. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973;52(11):2682–2689.
    1. Redman CW. Maternal plasma volume and disorders of pregnancy. Br Med J (Clin Res Ed) 1984;288(6422):955–956.
    1. Tapia HR, Johnson CE, Strong CG. Renin-angiotensin system in normal and in hypertensive disease of pregnancy. Lancet. 1972;2(7782):847–850.
    1. August P, Lenz T, Ales KL, Druzin ML, Edersheim TG, Hutson JM, Muller FB. et al. Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: deviations related to the development of superimposed preeclampsia. Am J Obstet Gynecol. 1990;163(5 Pt 1):1612–1621.
    1. Okuno S, Hamada H, Yasuoka M, Watanabe H, Fujiki Y, Yamada N, Sohda S. et al. Brain natriuretic peptide (BNP) and cyclic guanosine monophosphate (cGMP) levels in normal pregnancy and preeclampsia. J Obstet Gynaecol Res. 1999;25(6):407–410.
    1. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol. 2004;286(4):H1389–1393.
    1. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285(12):1607–1612.
    1. Sibai BM. Intergenerational factors: a missing link for preeclampsia, fetal growth restriction, and cardiovascular disease? Hypertension. 2008;51(4):993–994.
    1. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A. et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab. 2004;89(12):6239–6243.
    1. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53(6):944–951.
    1. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323(7323):1213–1217.
    1. Berends AL, de Groot CJ, Sijbrands EJ, Sie MP, Benneheij SH, Pal R, Heydanus R. et al. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension. 2008;51(4):1034–1041.
    1. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004;90(12):1499–1504.
    1. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ. 2007;335(7627):978.
    1. Thadhani R, Solomon CG. Preeclampsia--a glimpse into the future? N Engl J Med. 2008;359(8):858–860.
    1. Valdes G, Quezada F, Marchant E, von Schultzendorff A, Moran S, Padilla O, Martinez A. Association of remote hypertension in pregnancy with coronary artery disease: a case-control study. Hypertension. 2009;53(4):733–738.
    1. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326(7394):845.
    1. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009;40(4):1176–1180.
    1. Slemmons J, Bogert L. The uric acid content of maternal and fetal blood. J Biol Chem. 1971;32:63–69.
    1. Martin JN, Jr., May WL, Magann EF, Terrone DA, Rinehart BK, Blake PG. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol. 1999;180(6 Pt 1):1407–1414.
    1. Sagen N, Haram K, Nilsen ST. Serum urate as a predictor of fetal outcome in severe pre-eclampsia. Acta Obstet Gynecol Scand. 1984;63(1):71–75.
    1. Schaffer N, Dill L, Cadden J. Uric acid clearance in normal pregnancy and preeclampsia. J Clin Invest. 2003;22:201–206.
    1. Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, Kalache K. et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med. 2002;12(1):19–27.
    1. Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, Bravo SM. et al. Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology. 2000;217(2):371–376.
    1. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929–937.
    1. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW. et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK) Am J Kidney Dis. 2003;42(4):617–622.
    1. Spargo BH, Lichtig C, Luger AM, Katz AI, Lindheimer MD. The renal lesion in preeclampsia. Perspect Nephrol Hypertens. 1976;5:129–137.
    1. Kirsztajn GM. Determinacaourinaria de proteinas de baixo peso molecular. Diagnostico laboratorial emnefrologia. Sao Paulo: Sarvier; 2009. pp. 64–74.
    1. Thais AF, Gianna M, Nelson S. Preeclamsia (marker of chronic kidney disease): from genesis to future risk. J Bras Nephrol. 2012;34(1):87–93.
    1. Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, Rose CH. et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196(4):320. e321-327.
    1. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int. 2005;67(6):2101–2113.
    1. Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres Clin Obstet Gynaecol. 1994;8(2):443–468.
    1. Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981;60(4):267–276.
    1. Strevens H, Wide-Swensson D, Hansen A, Horn T, Ingemarsson I, Larsen S, Willner J. et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG. 2003;110(9):831–836.
    1. Subramanya A, Houghton D, Watnick S. Steroid-responsive idiopathic glomerular capillary endotheliosis: case report and literature review. Am J Kidney Dis. 2005;45(6):1090–1095.
    1. Laivuori H, Tikkanen MJ, Ylikorkala O. Hyperinsulinemia 17 years after preeclamptic first pregnancy. J Clin Endocrinol Metab. 1996;81(8):2908–2911.
    1. Hubel CA, Snaedal S, Ness RB, Weissfeld LA, Geirsson RT, Roberts JM, Arngrimsson R. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG. 2000;107(6):776–784.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir